Brokerages forecast that Johnson & Johnson (NYSE:JNJ) will report $20.21 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $20.07 billion and the highest is $20.62 billion. Johnson & Johnson posted sales of $18.11 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 11.6%. The business is expected to issue its next earnings results before the market opens on Tuesday, January 23rd.
According to Zacks, analysts expect that Johnson & Johnson will report full year sales of $20.21 billion for the current fiscal year, with estimates ranging from $76.21 billion to $80.09 billion. For the next financial year, analysts anticipate that the company will report sales of $81.56 billion per share, with estimates ranging from $80.72 billion to $82.66 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.68 EPS.
Several hedge funds have recently made changes to their positions in the company. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the second quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the second quarter worth about $124,000. Finally, Shine Investment Advisory Services Inc. bought a new position in shares of Johnson & Johnson during the second quarter worth about $177,000. 65.70% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.72 on Tuesday. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $377,620.00, a price-to-earnings ratio of 24.26, a P/E/G ratio of 2.84 and a beta of 0.80.
The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.